Skip to main content

Lymph Node Resection

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
TachoSil®N/A2 trials
Active Trials
NCT01920958Completed233Est. Mar 2014
NCT01500135Completed150Est. Dec 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaTachoSil®
TakedaTachoSil®

Clinical Trials (2)

Total enrollment: 383 patients across 2 trials

Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

Start: Mar 2012Est. completion: Dec 2015150 patients
Phase 3Completed

Use of Tachosil® for Lymph Sealing During Surgery

Start: Sep 2012Est. completion: Mar 2014233 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.